Palmitoylethanolamide,PEA,CAS No.544-31-0

  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Zhejiang

  • Validity to:

    Long-term effective

  • Last update:

    2018-04-21 17:46

  • Browse the number:

    450

Send an inquiries

Company Profile

Gihi Chemicals Co.,Limited

By certification [File Integrity]

Contact:jiehan(Mr.)  

Email:

Telephone:

Phone:

Area:Zhejiang

Address:Zhejiang

Website:http://www.gihichemicals.com/ http://www.ywcfdj.com/com/jiehan/

Product details

Basic Information

Product Name

Palmitoylethanolamide



Synonym

N-(2-HYDROXYETHYL)HEXADECANAMIDE;N-HEXADECANOYLETHANOLAMINE;PEA PALMIDROL;PALMITYLETHANOLAMIDE;PALMITOYLETHANOLAMIDE;PALMITOYLETHANOLAMIDE N-(2-HYDROXYETHYL)HEXADECANAMIDE;N-(2-Hydroxyethyl)-Hexadecanamid;Palmidrol

Product No

GIHI-01

Formula

C18H37NO2

Molecular Weight

299.49

CAS NO

544-31-0

EINECS  NO

208-867-9

Melting Point

97-98℃





Picture


Product Quality


No

Item

Specification

1

Appearance

White powder

2

Water

0.5% max

3

Storage

Stable under recommended storage conditions.

Introduction of Palmitoylethanolamide:


PEA(palmitoylethanolamide)

Palmitoylethanolamide: a natural painkiller. 

Its mechanism of action was discovered by the Nobel laureate professor Rita Levi-Montalcini.

Palmitoylethanolamide (PEA) is an endogenous , belonging to the class of nuclear factor agonists. PEA has been demonstrated to bind to a receptor in the cell-nucleus (a nuclear receptor) and exerts a great variety of biological functions related to chronic pain and inflammation. The main target is thought to be the  (PPAR-α).PEA also has affinity to cannabinoid-like G-coupled receptors  and .PEA cannot strictly be considered a classic  because it lacks affinity for the cannabinoid receptors  and .However, the presence of PEA (and other structurally related ) has been known to enhance anandamide activity by an "".

Several papers have demonstrated that an imbalance of the endocannabinoid system (ECS) and alterations in the levels of PEA occur in acute and chronic inflammation. For instance, during β-amyloid-induced neuroinflammation the deregulation of cannabinoid receptors and their endogenous  accompanies the development and progression of disease.

PEA has been shown to have ,neuroprotective, and  properties.

Chronic pain and neuropathic pain are indications for which there is high unmet need in the clinic. PEA has been tested in a variety of animal models for chronic and neuropathic pain. As cannabinoids, such as , have been proven to be effective in neuropathic pain states.The analgesic and antihyperalgesic effects of PEA in two models of acute and persistent pain seemed to be explained at least partly via the de novo neurosteroid synthesis. In chronic pain and inflammation model, PEA could prevent nerve formation and sprouting, mechanical allodynia, and PEA inhibited  activation, which is a hallmark for winding up in neuropathic pain. The mechanism of action of PEA as an analgesic and anti-inflammatory molecule is probably based on different aspects. PEA inhibits the release of both preformed and newly synthesised mast cell mediators, such as  and .PEA, as well as its analogue adelmidrol (di-amide derivative of azelaic acid), can both down-regulate mast cells.PEA reduces the expression of  (COX-2) and  (iNOS) and prevents IkB-alpha degradation and p65  nuclear translocation, the latter related to PEA as an endogenous PPAR-alpha agonist. In 2012 it became clear that PEA can also reduce reperfusion injury and the negative impact of shock on various outcome parameters, such as renal dysfunction, ischemic injury and inflammation, most probably via the PPAR-alpha pathway. Among the reperfusion and inflammation markers measured PEA could reduce the increase in creatinine, γGT, AST, nuclear translocation of NF-κBp65; kidney MPO activity and MDA levels, nitrotyrosine, PAR and adhesion molecules expression, the infiltration and activation of mastcells and apoptosis.

PEA seems to be produced in human as well as in animals as a biological response and a repair mechanism in chronic inflammation and chronic pain. In a model of visceral pain (inflammation of the ) PEA was able to attenuate the viscero-visceral hyper-reflexia induced by inflammation of the urinary bladder, one of the reasons why PEA is currently explored in the painful bladdersyndrome.In a different model for bladder pain, the turpentine-induced urinary bladder inflammation in the rat, PEA also attenuated a referred hyperalgesia in a dose-dependent way. Chronic pelvic pain in patients seem to respond favourably to a treatment with PEA.

Usage: PEA has been used as dietary supplement in many European countries and many other countries for many years.It also can be added in food. 

http://www.gihichemicals.com/